Cytokinetics Inc (NASDAQ: CYTK) is -18.03% lower on its value in year-to-date trading and has touched a low of $32.74 and a high of $71.60 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $39.81 in the last trading session, with the day’s loss setting it -1.25%.
Currently trading at $38.56, the stock is -4.96% and -11.06% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.01 million and changing -3.14% at the moment leaves the stock -23.80% off its SMA200. CYTK registered -46.12% loss for a year compared to 6-month loss of -29.74%. The firm has a 50-day simple moving average (SMA 50) of $43.3566 and a 200-day simple moving average (SMA200) of $50.60495.
The stock witnessed a -14.14% gain in the last 1 month and extending the period to 3 months gives it a -14.75%, and is 11.54% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.26% over the week and 7.58% over the month.
Cytokinetics Inc (CYTK) has around 498 employees, a market worth around $4.60B and $18.47M in sales. Profit margin for the company is -3191.11%. Distance from 52-week low is 17.78% and -46.15% from its 52-week high. The company has generated returns on investments over the last 12 months (-94.66%).
with sales reaching $2.77M over the same period.The EPS is expected to shrink by -8.38% this year, but quarterly earnings will post 93.30% year-over-year. Quarterly sales are estimated to grow 232.15% in year-over-year returns.
Cytokinetics Inc (CYTK) Top Institutional Holders
479.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 115.03% of the company’s shares. The shares outstanding are 118.21M, and float is at 116.06M with Short Float at 12.35%. Institutions hold 114.20% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 13.4317% of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 11.44 million shares valued at $619.69 million to account for 11.2218 of the shares outstanding. The other top investors are FMR LLC which holds 11.52 million shares representing 10.5485% and valued at over $624.32 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
#####
Cytokinetics Inc disclosed in a document filed with the SEC on Apr 10 ’25 that Blum Robert I (President & CEO) sold a total of 5,000 shares of the company’s common stock. The trade occurred on Apr 10 ’25 and was made at $36.77 per share for $0.18 million. Following the transaction, the insider now directly holds 0.42 million shares of the CYTK stock.
Still, SEC filings show that on Apr 08 ’25, Malik Fady Ibraham (EVP Research & Development) disposed off 2,000 shares at an average price of $36.18 for $72360.0. The insider now directly holds 140,255 shares of Cytokinetics Inc (CYTK).
